Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates.
The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A.
The company was founded in 2010 and is headquartered in La Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 24, 24 | -1.44 Decreased by -28.57% | -1.04 Decreased by -38.46% |
| Feb 28, 24 | -1.73 Decreased by -82.11% | -1.04 Decreased by -66.35% |
| Nov 9, 23 | -1.10 Decreased by -22.22% | -1.01 Decreased by -8.91% |
| Aug 7, 23 | -1.08 Decreased by -11.34% | -1.03 Decreased by -4.85% |
| May 8, 23 | -1.12 Decreased by -40.00% | -0.84 Decreased by -33.33% |
| Mar 6, 23 | -0.95 Decreased by -72.73% | -0.79 Decreased by -20.25% |
| Nov 7, 22 | -0.90 Decreased by -66.67% | -0.94 Increased by +4.26% |
| Aug 8, 22 | -0.97 Decreased by -76.36% | -0.78 Decreased by -24.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 119.00 K Decreased by -57.19% | -51.79 M Decreased by -27.41% | Decreased by -43.52 K% Decreased by -197.65% |
| Jun 30, 23 | 30.00 K Decreased by -95.78% | -47.05 M Decreased by -24.70% | Decreased by -156.84 K% Decreased by -2.86 K% |
| Mar 31, 23 | 17.00 K Decreased by -98.14% | -48.69 M Decreased by -45.39% | Decreased by -286.42 K% Decreased by -7.73 K% |
| Dec 31, 22 | 274.00 K Decreased by -90.34% | -40.91 M Decreased by -93.10% | Decreased by -14.93 K% Decreased by -1.90 K% |
| Sep 30, 22 | 278.00 K Decreased by -88.92% | -40.65 M Decreased by -97.51% | Decreased by -14.62 K% Decreased by -1.68 K% |
| Jun 30, 22 | 711.00 K Decreased by -22.55% | -37.73 M Decreased by -82.19% | Decreased by -5.31 K% Decreased by -135.24% |
| Mar 31, 22 | 915.00 K Increased by +6.03% | -33.49 M Decreased by -73.63% | Decreased by -3.66 K% Decreased by -63.76% |
| Dec 31, 21 | 2.84 M Increased by +2.16% | -21.19 M Decreased by -20.06% | Decreased by -747.14% Decreased by -17.52% |